Preop trastuzumab eradicates tumors in 45.5% of HER2+ patients
New data presented as part of a late-breaking plenary session at the 6th European Breast Cancer Conference in Berlin showed that neoadjuvant trastuzumab (Herceptin) in combination with standard chemotherapy produced a pathological complete response rate in 45.5% of women with HER2-positive early breast cancer.
New data presented as part of a late-breaking plenary session at the 6th European Breast Cancer Conference in Berlin showed that neoadjuvant trastuzumab (Herceptin) in combination with standard chemotherapy produced a pathological complete response rate in 45.5% of women with HER2-positive early breast cancer.
The GeparQuattro study is a randomized phase III study that enrolled 1,510 breast cancer patients. The 453 patients with HER2-positive disease received four cycles of epirubicin plus cyclophosphamide plus trastuzumab. Patients then received one of three treatment options: four cycles of docetaxel (Taxotere) plus trastuzumab; docetaxel plus capecitabine (Xeloda) plus trastuzumab concomitantly; or docetaxel plus trastuzumab followed by capecitabine plus trastuzumab.
Treatment Combinations for HER2-Positive Breast Cancer
March 7th 2013As part of our coverage for the 30th Annual Miami Breast Cancer Conference, we bring you an interview with Dr. Mark Pegram, director of the breast cancer program at the Stanford Women’s Cancer Center and codirector of the molecular therapeutics program. Dr. Pegram will be discussing the potential for novel HER2 combination therapies at the conference.
